These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33166772)

  • 1. Developing univariate neurodegeneration biomarkers with low-rank and sparse subspace decomposition.
    Wang G; Dong Q; Wu J; Su Y; Chen K; Su Q; Zhang X; Hao J; Yao T; Liu L; Zhang C; Caselli RJ; Reiman EM; Wang Y;
    Med Image Anal; 2021 Jan; 67():101877. PubMed ID: 33166772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studying APOE ɛ4 Allele Dose Effects with a Univariate Morphometry Biomarker.
    Wang G; Zhou W; Kong D; Qu Z; Ba M; Hao J; Yao T; Dong Q; Su Y; Reiman EM; Caselli RJ; Chen K; Wang Y;
    J Alzheimers Dis; 2022; 85(3):1233-1250. PubMed ID: 34924383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Graph Convolutional Network Based on Univariate Neurodegeneration Biomarker for Alzheimer's Disease Diagnosis.
    Qu Z; Yao T; Liu X; Wang G
    IEEE J Transl Eng Health Med; 2023; 11():405-416. PubMed ID: 37492469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Binette AP; Vogel JW; Klein G; Borroni E; Tonietto M; Strandberg O; Mattsson-Carlgren N; Palmqvist S; Pontecorvo MJ; Iaccarino L; Stomrud E; Ossenkoppele R; Smith R; Hansson O;
    JAMA Neurol; 2023 Jun; 80(6):614-623. PubMed ID: 37155176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker Extraction Based on Subspace Learning for the Prediction of Mild Cognitive Impairment Conversion.
    Li Y; Fang Y; Wang J; Zhang H; Hu B
    Biomed Res Int; 2021; 2021():5531940. PubMed ID: 34513992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
    Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.
    van Maurik IS; Zwan MD; Tijms BM; Bouwman FH; Teunissen CE; Scheltens P; Wattjes MP; Barkhof F; Berkhof J; van der Flier WM;
    JAMA Neurol; 2017 Dec; 74(12):1481-1491. PubMed ID: 29049480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Federated Morphometry Feature Selection for Hippocampal Morphometry Associated Beta-Amyloid and Tau Pathology.
    Wu J; Dong Q; Zhang J; Su Y; Wu T; Caselli RJ; Reiman EM; Ye J; Lepore N; Chen K; Thompson PM; Wang Y
    Front Neurosci; 2021; 15():762458. PubMed ID: 34899166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2017 Apr; 13(4):e1-e85. PubMed ID: 28342697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Prediction of Imminent Progression to Clinically Significant Memory Decline Using Surface Multivariate Morphometry Statistics and Sparse Coding.
    Stonnington CM; Wu J; Zhang J; Shi J; Bauer Iii RJ; Devadas V; Su Y; Locke DEC; Reiman EM; Caselli RJ; Chen K; Wang Y;
    J Alzheimers Dis; 2021; 81(1):209-220. PubMed ID: 33749642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal changes in surface based brain morphometry measures in amnestic mild cognitive impairment and Alzheimer's Disease.
    Bachmann T; Schroeter ML; Chen K; Reiman EM; Weise CM;
    Neuroimage Clin; 2023; 38():103371. PubMed ID: 36924681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
    Karikari TK; Benedet AL; Ashton NJ; Lantero Rodriguez J; Snellman A; Suárez-Calvet M; Saha-Chaudhuri P; Lussier F; Kvartsberg H; Rial AM; Pascoal TA; Andreasson U; Schöll M; Weiner MW; Rosa-Neto P; Trojanowski JQ; Shaw LM; Blennow K; Zetterberg H;
    Mol Psychiatry; 2021 Feb; 26(2):429-442. PubMed ID: 33106600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using machine learning to quantify structural MRI neurodegeneration patterns of Alzheimer's disease into dementia score: Independent validation on 8,834 images from ADNI, AIBL, OASIS, and MIRIAD databases.
    Popuri K; Ma D; Wang L; Beg MF
    Hum Brain Mapp; 2020 Oct; 41(14):4127-4147. PubMed ID: 32614505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
    Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR;
    JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.